summit trial tirzepatide Improves HFpEF Symptoms and Outcomes Treatment with #tirzepatide in the
Pay in 4 interest-free payments of $7.00 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Live Spec
Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening heart failure and improved health status in patients with #HFpEF and obesity. https: t.co O9iU9a1Xgw SUMMIT trial results presented at #AHA24 show tirzepatide reduced the risk of worsening heart failure events and improved quality of life in patients with #HFpEF and obesity. Cardiologists now have an ever expanding Another "Positive" Heart Failure Trial that Falls Short New data from the SUMMIT trial reveals that long term tirzepatide (Zepbound) may significantly improve kidney function in patients with obesity, chronic kidney disease (CKD), and heart failure with preserved ejection fraction ( In an earlier analysis of the SURMOUNT 1 trial, tirzepatide (a dual glucose dependent insulinotropic polypeptide [GIP] and glucagon like peptide 1 [GLP 1] receptor agonist) was shown to provide substantial and sustained reductions in body weight
Store: skorenge.com · Domain: skorenge.com





















